Macular Edema clinical trials at UCSF
2 in progress, 1 open to eligible people
Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center
open to eligible people ages 18 years and up
The study will evaluate whether videos can improve understanding of diabetic eye disease, and follow-up rates in the eye clinic.
San Francisco, California
RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Sorry, in progress, not accepting new patients
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1-4) and Phase II (Part 5). Phase I investigated the safety of RO7446603 following a single and multiple intravitreal (IVT) doses as monotherapy or co-administered with IVT aflibercept or IVT faricimab (in separate injections). Phase II will investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of two dose levels of RO7446603 in combination with faricimab, with the two drugs co-mixed and administered as a single IVT injection, compared to faricimab alone. The first participant was enrolled in the Phase I segment on June 22, 2022. Phase I has been completed.
San Francisco, California and other locations
Our lead scientists for Macular Edema research studies include Sriranjani Padmanabhan, MD.
Last updated: